Reassessment of the risk of birth defects due to Zika virus in Guadeloupe, 2016.
Adult
Cohort Studies
Congenital Abnormalities
/ epidemiology
Female
Guadeloupe
/ epidemiology
Humans
Infant, Newborn
Microcephaly
/ epidemiology
Middle Aged
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
Prospective Studies
Zika Virus
/ isolation & purification
Zika Virus Infection
/ complications
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
22
09
2020
accepted:
08
12
2020
entrez:
3
3
2021
pubmed:
4
3
2021
medline:
25
6
2021
Statut:
epublish
Résumé
In the French Territories in the Americas (FTA), the risk of birth defects possibly associated with Zika virus (ZIKV) infection was 7.0% (95%CI: 5.0 to 9.5) among foetuses/infants of 546 women with symptomatic RT-PCR confirmed ZIKV infection during pregnancy. Many of these defects were isolated measurement-based microcephaly (i.e. without any detected brain or clinical abnormalities) or mild neurological conditions. We wanted to estimate the proportion of such minor findings among live births of women who were pregnant in the same region during the outbreak period but who were not infected with ZIKV. In Guadeloupe, pregnant women were recruited at the time of delivery and tested for ZIKV infection. The outcomes of live born infants of ZIKV non-infected women were compared to those of ZIKV-exposed live born infants in Guadeloupe, extracted from the FTA prospective cohort. Of 490 live born infants without exposure to ZIKV, 42 infants (8.6%, 95%CI: 6.2-11.4) had mild abnormalities that have been described as 'potentially linked to ZIKV infection'; all but one of these was isolated measurement-based microcephaly. Among the 241 live born infants with ZIKV exposure, the proportion of such abnormalities, using the same definition, was similar (6.6%, 95%CI: 3.8-10.6). Isolated anthropometric abnormalities and mild neurological conditions were as prevalent among infants with and without in-utero ZIKV exposure. If such abnormalities had not been considered as 'potentially linked to ZIKV' in the original prospective cohort in Guadeloupe, the overall estimate of the risk of birth defects considered due to the virus would have been significantly lower, at approximately 1.6% (95% CI: 0.4-4.1). ClinicalTrials.gov (NCT02916732).
Sections du résumé
BACKGROUND
In the French Territories in the Americas (FTA), the risk of birth defects possibly associated with Zika virus (ZIKV) infection was 7.0% (95%CI: 5.0 to 9.5) among foetuses/infants of 546 women with symptomatic RT-PCR confirmed ZIKV infection during pregnancy. Many of these defects were isolated measurement-based microcephaly (i.e. without any detected brain or clinical abnormalities) or mild neurological conditions. We wanted to estimate the proportion of such minor findings among live births of women who were pregnant in the same region during the outbreak period but who were not infected with ZIKV.
METHODS
In Guadeloupe, pregnant women were recruited at the time of delivery and tested for ZIKV infection. The outcomes of live born infants of ZIKV non-infected women were compared to those of ZIKV-exposed live born infants in Guadeloupe, extracted from the FTA prospective cohort.
RESULTS
Of 490 live born infants without exposure to ZIKV, 42 infants (8.6%, 95%CI: 6.2-11.4) had mild abnormalities that have been described as 'potentially linked to ZIKV infection'; all but one of these was isolated measurement-based microcephaly. Among the 241 live born infants with ZIKV exposure, the proportion of such abnormalities, using the same definition, was similar (6.6%, 95%CI: 3.8-10.6).
CONCLUSIONS
Isolated anthropometric abnormalities and mild neurological conditions were as prevalent among infants with and without in-utero ZIKV exposure. If such abnormalities had not been considered as 'potentially linked to ZIKV' in the original prospective cohort in Guadeloupe, the overall estimate of the risk of birth defects considered due to the virus would have been significantly lower, at approximately 1.6% (95% CI: 0.4-4.1).
TRIAL REGISTRATION
ClinicalTrials.gov (NCT02916732).
Identifiants
pubmed: 33657112
doi: 10.1371/journal.pntd.0009048
pii: PNTD-D-20-01698
pmc: PMC7928479
doi:
Banques de données
ClinicalTrials.gov
['NCT02916732']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009048Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Prenat Diagn. 2010 Jun;30(6):531-9
pubmed: 20509152
BMC Public Health. 2018 Jan 12;18(1):130
pubmed: 29329574
PLoS One. 2017 Mar 3;12(3):e0172910
pubmed: 28257473
Pediatrics. 2018 Feb;141(2):
pubmed: 29305391
N Engl J Med. 2018 Mar 15;378(11):985-994
pubmed: 29539287
Am J Trop Med Hyg. 2018 Jun;98(6):1860-1862
pubmed: 29692307
Lancet Infect Dis. 2018 Mar;18(3):328-336
pubmed: 29242091
Pediatrics. 2018 Feb;141(Suppl 2):S154-S160
pubmed: 29437048
BMJ. 2018 Oct 31;363:k4431
pubmed: 30381296
BJOG. 2010 May;117(6):660-6
pubmed: 20374608
PLoS One. 2018 Aug 15;13(8):e0201452
pubmed: 30110370
PLoS One. 2019 Jul 17;14(7):e0219095
pubmed: 31314794
Diagn Microbiol Infect Dis. 2018 Jan;90(1):26-30
pubmed: 29107414
Ultrasound Obstet Gynecol. 2017 Jun;49(6):729-736
pubmed: 28078779
Emerg Infect Dis. 2019 Jun;25(6):1153-1160
pubmed: 31107211
Lancet Infect Dis. 2016 Jun;16(6):653-660
pubmed: 26897108
Lancet Diabetes Endocrinol. 2014 Oct;2(10):773
pubmed: 25258202
Prog Retin Eye Res. 2018 Sep;66:85-106
pubmed: 29698814
BMJ. 2016 Sep 13;354:i4721
pubmed: 27623840
Lancet Child Adolesc Health. 2018 Mar;2(3):205-213
pubmed: 30169255
J Clin Microbiol. 2019 Oct 23;57(11):
pubmed: 31462546
Am J Obstet Gynecol. 2017 Mar;216(3):292.e1-292.e8
pubmed: 28153665
BJOG. 2016 Sep;123 Suppl 3:48-55
pubmed: 27627597
Lancet Infect Dis. 2021 Apr;21(4):537-545
pubmed: 33068528
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):615-621
pubmed: 28617773
BMC Res Notes. 2017 Sep 6;10(1):457
pubmed: 28877754
JAMA Pediatr. 2017 Mar 1;171(3):288-295
pubmed: 27812690
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):91-96
pubmed: 29370151
Reprod Toxicol. 2006 May;21(4):390-8
pubmed: 16580940
Lancet Diabetes Endocrinol. 2014 Oct;2(10):781-92
pubmed: 25009082
N Engl J Med. 2016 Dec 15;375(24):2321-2334
pubmed: 26943629
Clin Infect Dis. 2018 Apr 3;66(8):1173-1180
pubmed: 29300893
BMJ. 2017 Nov 21;359:j5018
pubmed: 29162597
Clin Microbiol Rev. 2013 Jan;26(1):86-102
pubmed: 23297260
MMWR Morb Mortal Wkly Rep. 2018 Aug 10;67(31):858-867
pubmed: 30091967
Sci Rep. 2020 Feb 4;10(1):1752
pubmed: 32019953
Lancet. 2016 Apr 30;387(10030):1811-2
pubmed: 27103126